Patient | Patient 1 | Patient 2 | Patient 3 |
---|---|---|---|
Age (years) | 49 | 87 | 35 |
Type of MG | Generalized | Generalized | Generalized |
Antibodies | Double seronegative | Positive for anti-AchR | Positive for anti-AchR |
Treatment | PDN 10 mg/48 h and MA 360 mg/12 h | PDN 10 mg/48 h | PDN 10 mg/48 h and MA 540 mg/24 h |
MGFA prior to taking melatonin | 0 | I | I |
MGFA-PIS prior to taking melatonin | PR | MM1 | MM3 |
ADL score prior to taking melatonin | 0 | 0 | 2 |
Melatonin dose | 1.95 mg/day | 1.9 mg/day | 1.95 mg/day |
Time from start of melatonin to worsening | 3 weeks | 2 days | 7 days |
Deterioration in ADL score | 5 | 4 | 7 |
Melatonin ceased | Yes | No | Yes |
Treatment received | Increased dose of PDN | Increased dose of PDN | Increased dose of PDN plus IVIG |
Time from cessation of melatonin to improvement | 5 weeks | – | 6 weeks |